VERACYTE, INC. (VCYT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US92337F1075
VERACYTE, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 517.15 m USD |
| Gross profit | 362.53 m USD |
| Operating income | 57.78 m USD |
| EBIT | 68.20 m USD |
| Net income | 66.35 m USD |
| Diluted EPS – continuing operations | 0.82 USD |
Full history since 2010, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About VERACYTE, INC.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
More stocks
- Red Avenue New Materials Group Co Ltd (603650.SS)
- 51Talk Online Education Group (COE)
- QinetiQ Group PLC (QQ.L)
- Talkweb Information System Co Ltd (002261.SZ)
- Shanghai Xinmei Real Estate Co Ltd Class A (600732.SS)
- Zuger Kantonalbank (ZUGER.SW)
- Atmus Filtration Technologies Inc. (ATMU)
- SUZHOU KEMATEK INC (301611.SZ)
- Nantong Jianghai Capacitor Co Ltd (002484.SZ)
- Centre Testing Intl Shenzhen (300012.SZ)
- Stadler Rail AG (SRAIL.SW)
- Bluestar Adisseo Co (600299.SS)
Not investment advice. All data without warranty, price as of 02.11.2026. Details in the risk notice.